NightHawk Biosciences (NHWK) has released an update to notify the public and investors about an entry into a material definitive agreement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NightHawk Biosciences, Inc. sold its rights in an exclusive license agreement for certain cancer and disease treatment-related provisional patent applications and know-how to Kopfkino IP, LLC for $1,000,000. Separately, Elusys Holdings Inc. bought a $2,250,000 convertible note from NightHawk, bearing 1% interest and maturing in one year, which may convert into 5,727,960 shares of NightHawk’s common stock at $0.39281 per share, subject to stockholder approval and potential adjustments related to subsequent public financing within 60 days of the note’s issue.
For further insights into NHWK stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
